STARLIMS

STARLIMS is a laboratory informatics software brand whose principal offering is a laboratory information management system, commonly abbreviated LIMS. The business was established in Israel in 1986 by Itschak Friedman and Dinu Toiba and initially developed and sold software for managing laboratory information and workflows. Its products were intended to help laboratories organize samples, tests, results, instruments, users, and compliance-related records in a controlled digital environment. The company expanded beyond its original Israeli base and built a particularly visible presence in the United States, the United Kingdom, and Hong Kong. By 2005, its software had been installed by the United States Centers for Disease Control and Prevention and by health authorities in twelve U.S. states. These deployments placed STARLIMS in public-health and regulated laboratory settings, where traceability, standardized procedures, data integrity, and access control are important requirements. By that period, the company had developed from a specialist software provider into a supplier serving institutional and enterprise laboratory customers. STARLIMS later shifted its product presentation toward web-based delivery. Rather than functioning solely as a locally installed laboratory application, the platform was offered as a web application, supporting centralized access and administration across laboratory environments. This direction aligned the brand with broader enterprise software trends, although the available reference material does not establish a specific subscription model or detailed cloud architecture. The company completed an initial public offering in the United States in 2007. Its public-company period ended when Abbott Laboratories acquired STARLIMS in 2009 for $123 million. At the time of the transaction, STARLIMS had approximately 160 employees, and most of its operations and sales were concentrated in the United States, the United Kingdom, and Hong Kong. Abbott planned to integrate STARLIMS products with its other health information technology activities, linking the acquisition to its wider clinical diagnostics business. In 2014, Abbott renamed the subsidiary Abbott Informatics. The change placed the STARLIMS business within Abbott's broader informatics structure, although the STARLIMS product identity continued to be associated with laboratory information management software. Abbott sold the business in July 2021 to Francisco Partners, a technology-focused private-equity investor, after which the STARLIMS name again became the principal external identity of the business. The brand expanded its research-software scope in August 2023 by acquiring Labstep, a London-based electronic laboratory notebook platform. Labstep extended STARLIMS beyond traditional laboratory information management toward research documentation and electronic experiment records. The financial terms were not disclosed. In January 2026, Francisco Partners sold STARLIMS to private-equity firm Turn/River Capital for an undisclosed amount. STARLIMS therefore remains an active specialist enterprise-software brand, operating in laboratory informatics and adjacent research workflow categories, but detailed information about its current management, headquarters, ownership structure, and market footprint is not established in the supplied reference material.

STARLIMS originated in Israel in 1986, when Itschak Friedman and Dinu Toiba founded a company focused on laboratory information management software. Its early business centered on developing and selling LIMS applications, which are used to structure laboratory operations and records. Such systems can support sample handling, test processing, result management, laboratory workflows, and controlled access to information, although the supplied reference does not provide a detailed breakdown of the original product modules. The business gained international traction during the following decades. By 2005, STARLIMS software had been deployed by the United States Centers for Disease Control and Prevention and by health authorities in twelve U.S. states. These installations demonstrated the company's relevance to public-health laboratories and other organizations operating in regulated environments. The company's principal operations and sales were concentrated in the United States, United Kingdom, and Hong Kong. By the time of its acquisition by Abbott, STARLIMS had approximately 160 employees. STARLIMS became a U.S.-listed company through an initial public offering in 2007. Its independent public-company period was relatively short. Abbott Laboratories acquired the company in 2009 for $123 million, with Itschak Friedman serving as chief executive until the acquisition. Abbott's stated intention was to combine STARLIMS' products with its other health information technology businesses and use the capabilities in support of its clinical diagnostics activities. At the time of the transaction, the software was available as a web application, reflecting the brand's movement toward browser-based enterprise delivery. In 2014, Abbott changed the subsidiary's name from STARLIMS to Abbott Informatics. This renamed structure placed the laboratory software business inside Abbott's wider informatics operations. Abbott later sold the business to Francisco Partners in July 2021. Following that transaction, STARLIMS again operated as an identifiable laboratory-informatics brand under private-equity ownership. The portfolio expanded in August 2023, when STARLIMS acquired Labstep, a London-based electronic laboratory notebook platform. Electronic laboratory notebooks address a related but distinct research need: recording experimental work, procedures, observations, and associated documentation in a digital environment. The acquisition consequently broadened STARLIMS' scope from core laboratory information management toward research documentation and workflow software. The purchase price was not disclosed. In January 2026, Francisco Partners sold STARLIMS to Turn/River Capital for an undisclosed amount. The transaction marked another ownership change in the company's history, following its periods as a public company, an Abbott subsidiary, and a Francisco Partners portfolio company. On the basis of the supplied material, STARLIMS remains an active enterprise laboratory-software brand. Its historical development is defined by specialization in LIMS, adoption by public-health and regulated laboratories, transition to web-based delivery, integration into Abbott Informatics, subsequent private-equity ownership, and expansion into electronic laboratory notebooks through Labstep.

1. 2026Acquired by Turn/River Capital

   Francisco Partners sold STARLIMS to Turn/River Capital for an undisclosed amount.

   Source
2. 2023Labstep acquisition

   STARLIMS acquired London-based electronic laboratory notebook provider Labstep.

   Source
3. 2021Sold to Francisco Partners

   Abbott sold STARLIMS to Francisco Partners in July 2021.

   Source
4. 2014Renamed Abbott Informatics

   Abbott changed the subsidiary's name from STARLIMS to Abbott Informatics.

   Source
5. 2009Acquired by Abbott Laboratories

   Abbott Laboratories acquired STARLIMS for $123 million and planned to integrate its products with Abbott's health information technology activities.

   Source
6. 2007U.S. initial public offering

   The company completed an initial public offering in the United States.

   Source
7. 2005Adoption by public-health organizations

   STARLIMS software was installed at the U.S. Centers for Disease Control and Prevention and by health authorities in twelve U.S. states.

   Source
8. 1986Company founded in Israel

   Itschak Friedman and Dinu Toiba founded the business in Israel to develop and sell laboratory information management software.

   Source

Enterprise laboratory informatics software for regulated, research, public-health, and other laboratory environments requiring structured workflow management, traceable data, and controlled access.

• STARLIMSLaboratory information management system

  STARLIMS is the brand's core laboratory information management system. It is designed to support the organization of laboratory data and workflows in enterprise and regulated settings. The software was offered as a web application by the time of Abbott's acquisition, and its documented users included public-health organizations such as the U.S. Centers for Disease Control and Prevention and state health authorities.

• LabstepElectronic laboratory notebook

  Labstep is a London-based electronic laboratory notebook platform acquired by STARLIMS in 2023. It extends the portfolio into digital research documentation, helping laboratory users record experimental work and related information in an electronic environment. The supplied sources do not specify the platform's detailed modules or current branding after the acquisition.

• 2026Sale to Turn/River CapitalM&A

  STARLIMS was owned by Francisco Partners after Abbott's 2021 divestiture.

  What changed. Francisco Partners sold STARLIMS to private-equity firm Turn/River Capital for an undisclosed amount.

  Aftermath. Turn/River Capital became the brand's owner and portfolio-company sponsor.

  Acquisition price. (2026)

  Source
• 2023Acquire LabstepM&A

  STARLIMS sought to broaden its laboratory software portfolio beyond core laboratory information management.

  What changed. STARLIMS acquired Labstep, a London-based electronic laboratory notebook platform, for an undisclosed amount.

  Aftermath. The acquisition expanded the brand's stated product scope into electronic research documentation and laboratory notebook workflows.

  Acquisition price. (2023)

  Source
• 2014Rename the subsidiary Abbott InformaticsStrategy

  After acquiring STARLIMS, Abbott incorporated the business into its broader health information technology activities.

  What changed. Abbott changed the subsidiary's name from STARLIMS to Abbott Informatics.

  Aftermath. The business continued within Abbott's informatics organization before being sold to Francisco Partners in 2021.

  Source
• 2009Accept Abbott Laboratories acquisitionM&A

  STARLIMS had become an international laboratory-software provider with approximately 160 employees and substantial sales and operations in the United States, United Kingdom, and Hong Kong.

  What changed. Abbott Laboratories acquired the company for $123 million and intended to integrate its products with Abbott's other health information technology businesses.

  Aftermath. STARLIMS became part of Abbott's informatics activities and was later renamed Abbott Informatics in 2014.

  Acquisition price. $123 million (2009)

  Source

• 2026Francisco Partners sells STARLIMS to Turn/River Capital

  Francisco Partners sold STARLIMS to private-equity firm Turn/River Capital. The reported transaction value was not disclosed.

  M&A
  Source
• 2023STARLIMS acquires Labstep

  STARLIMS acquired Labstep, a London-based electronic laboratory notebook platform. The transaction broadened the brand's research informatics portfolio; financial terms were not disclosed.

  M&AProduct launch
  Source
• 2021Abbott sells STARLIMS to Francisco Partners

  Francisco Partners acquired STARLIMS from Abbott in July 2021, returning the business to ownership by a technology-focused private-equity firm.

  M&A
  Source
• 2014Abbott renames STARLIMS subsidiary Abbott Informatics

  Abbott changed the name of its STARLIMS subsidiary to Abbott Informatics as part of its broader health-information-technology organization.

  Leadership changeOther
  Source
• 2009Abbott Laboratories acquires STARLIMS

  Abbott Laboratories acquired STARLIMS for $123 million. At the time, the company had about 160 employees and most of its operations and sales were in the United States, United Kingdom, and Hong Kong.

  M&A
  Source
• 2007STARLIMS completes U.S. initial public offering

  STARLIMS held an initial public offering in the United States, creating a public-market phase before its subsequent acquisition by Abbott Laboratories.

  Other
  Source

1. Starlims